From the Department of Emergency Medicine, University of Rochester Medical Center, Rochester, New York.
Department of Medicine, Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, and.
Allergy Asthma Proc. 2023 Jul 1;44(4):283-290. doi: 10.2500/aap.2023.44.230023.
Guidelines recommend patients with anaphylaxis are prescribed epinephrine autoinjectors (EAI), carry the EAI with them, and are referred to an allergist. There also are barriers to EAI administration, such as acquiring the medication, having it available, recognizing when to use it, and administering it appropriately. The objective was to describe how often patients with anaphylaxis discharged from the emergency department (ED) receive an EAI prescription and allergist referral; also, to assess the frequency of EAI pick-up by the patient from the outpatient pharmacy, out-of-pocket cost, change in EAI device during dispensing, and if patient training on EAI use and allergist follow-up occurred. Patient-specific factors associated with the occurrence of these variables were investigated. This was a retrospective, observational study of adult and pediatric ED patients who presented with anaphylaxis between July and December 2020. Data were collected from medical records and telephone calls to outpatient pharmacies and included patient demographics; ED treatment; EAI prescribing, EAI pick-up from the outpatient pharmacy, and cost; device changes; EAI training; and allergist referral and follow-up. Data are presented descriptively, and bivariate analyses were used for comparisons between patient-specific factors and incidence of EAI prescribing, patient pick-up, and allergist referral. A total of 102 patients were included; mean age ± standard deviation 34 ± 7 years, 52% were < 18 years of age; and 54% had a history of allergy and/or anaphylaxis. EAI prescribing occurred in 79% of the patients. Of these, 71% picked up the EAI from the outpatient pharmacy, the median cost to the patient was $5 (range, $0-$379), 18% had an EAI device change at dispensing, and 23% received EAI training. Allergist referral occurred in 22%, and 28% followed up with an allergist within 60 days. Presenting symptoms of mucosal edema and respiratory stridor were associated with the occurrence of EAI prescribing. Presenting symptoms of respiratory wheezing, hoarseness, throat itching, skin flushing and allergist referral from the ED were associated with the occurrence of EAI pick-up from the outpatient pharmacy. Overall, 79% of ED patients with anaphylaxis had an EAI prescribed and 22% had an allergist referral; 71% picked up the EAI from the outpatient pharmacy, EAI dispensing changes occurred, and training was infrequent. Collaboration between emergency medicine clinicians, allergists, and pharmacists is needed to streamline treatment and follow-up.
指南建议过敏反应患者开肾上腺素自动注射器(EAI),随身携带 EAI,并转介给过敏症专家。但是,EAI 的管理也存在障碍,例如获取药物、确保药物可用、识别何时使用以及正确使用。目的是描述从急诊科(ED)出院的过敏反应患者接受 EAI 处方和过敏症专家转介的频率;还评估患者从门诊药房取 EAI 的频率、自付费用、配药期间 EAI 设备的变化,以及是否对患者进行 EAI 使用和过敏症专家随访的培训。研究了与这些变量发生相关的患者特定因素。这是一项回顾性、观察性研究,纳入了 2020 年 7 月至 12 月期间因过敏反应到急诊科就诊的成人和儿科患者。数据来自病历和对门诊药房的电话访问,包括患者人口统计学数据;ED 治疗;EAI 处方、EAI 从门诊药房取药和费用;设备变更;EAI 培训;以及过敏症专家转诊和随访。数据以描述性方式呈现,并使用双变量分析比较患者特定因素与 EAI 处方、患者取药和过敏症专家转诊的发生率。共纳入 102 例患者,平均年龄 ± 标准差为 34 ± 7 岁,52%年龄<18 岁;54%有过敏和/或过敏反应史。79%的患者开具了 EAI 处方。其中,71%从门诊药房取走 EAI,患者的中位数费用为 5 美元(范围 0-379 美元),18%在配药时发生 EAI 设备变更,23%接受了 EAI 培训。22%的患者转诊给过敏症专家,28%的患者在 60 天内接受过敏症专家的随访。就诊时出现黏膜水肿和呼吸喘鸣的症状与 EAI 处方的开具相关。就诊时出现呼吸喘息、声音嘶哑、喉咙瘙痒、皮肤潮红和 ED 时的过敏症专家转诊与从门诊药房取 EAI 相关。总体而言,79%的过敏反应急诊科患者开具了 EAI 处方,22%的患者转诊给过敏症专家;71%从门诊药房取走 EAI,EAI 配药发生变化,且培训频率较低。需要急诊医学临床医生、过敏症专家和药剂师之间的合作,以简化治疗和随访。